Marko, Martha http://orcid.org/0000-0002-9063-0465
Singh, Nishita
Ospel, Johanna M.
Uchida, Kazutaka
Almekhlafi, Mohammed A.
Demchuk, Andrew M.
Nogueira, Raul G.
McTaggart, Ryan A.
Poppe, Alexandre Y.
Rempel, Jeremy L.
Tymianski, Michael
Hill, Michael D.
Goyal, Mayank
Menon, Bijoy K.
,
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 21 September 2023
Accepted: 9 November 2023
First Online: 18 December 2023
Declarations
:
: J.M. Ospel: funds from the University of Basel Research Foundation, Julia Bangerter Rhyner Foundation, Freiwillige Akademische Gesellschaft Basel. M.D. Hill: grants from Canadian Institutes for Health Research, Alberta Innovates, NoNO, Heart & Stroke Foundation of Canada, National Institutes of Neurological Disorders and Stroke, Covidien, Boehringer-Ingleheim, Stryker, and Medtronic; fees from Merck; patent for systems of acute stroke diagnosis; stock in Calgary Scientific. M. Goyal: personal fees from Mentice, Medtronic, Microvention, Stryker; patent to systems of acute stroke diagnosis. B.K. Menon: shares in Circle NVI; patent for systems of triage in acute stroke. M. Marko, N. Singh, K. Uchida, M.A. Almekhlafi, A.M. Demchuk, R.G. Nogueira, R.A. McTaggart, A.Y. Poppe, J.L. Rempel and M. Tymianski declare that they have no competing interests.
: For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case. Ethics approval for the ESCAPE-NA1 trial was provided by local ethics boards. Patients or their legal representatives signed an informed consent form prior to enrolment in the trial.